Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Yasuki Takano"'
Autor:
Yoichiro Ogama, Nahoko Kasahara-Ito, Yuji Kumagai, Hiroyuki Fukase, Yasuki Takano, Tomohisa Saito, Kimio Terao, Yasuhiro Ohba, Noboru Nakamichi, Tomoko Ichihara, Sachiya Ikeda, Sumire Shimada
Publikováno v:
Drug Research. 67:349-357
Tofogliflozin is a selective oral inhibitor of sodium-glucose co-transporter 2 for treatment of type 2 diabetes mellitus. The pharmacokinetics, pharmacodynamics, and safety of tofogliflozin were investigated in healthy male subjects. Three studies we
Autor:
Dietmar Schwab, Satofumi Iida, Agnès Portron, Sachiya Ikeda, Nahoko Kasahara-Ito, Tomohisa Saito, Yasuki Takano
Publikováno v:
Drug research. 69(6)
Purpose Tofogliflozin is an orally available selective inhibitor of sodium-glucose co-transporter 2 for treatment of type 2 diabetes mellitus (T2DM). Two studies were conducted to evaluate the effect of renal impairment on pharmacokinetics and pharma
Autor:
Kumiko Miyata, Tomohisa Saito, M. Harigai, Yasuhiro Ohba, Yasuki Takano, Kimio Terao, H. Fukase, Satofumi Iida, Sachiya Ikeda, N. Kasahara
Publikováno v:
Drug research. 66(2)
Objective: Tofogliflozin is an oral hypoglycemic agent with a novel mechanism of action that reduces blood glucose levels by promoting glucose excretion in urine, achieved by selectively inhibiting sodium-glucose co-transporter 2 (SGLT2). We evaluate
Autor:
Nahoko Kasahara-Ito, Hiroyuki Fukase, Yoichiro Ogama, Tomohisa Saito, Yasuhiro Ohba, Sumire Shimada, Yasuki Takano, Tomoko Ichihara, Kimio Terao, Noboru Nakamichi, Yuji Kumagai, Sachiya Ikeda
Publikováno v:
Drug Research; Jun2017, Vol. 67 Issue 6, p349-357, 9p, 3 Charts, 4 Graphs